We’re driven to partner with you to solve difficult scientific problems, complementing your strategies with expertise in complex method development on multiple technology platforms, validation, and transfer. Our Research & Development team serves as an extension of your laboratory, with unique skills in technology platform selection and protocol design.
Viracor Eurofins leverages over 16 different technology platforms, and accepts a broad range of specimen types, widening our capabilities and enabling us to customize testing to your trial’s exact needs, together with the scalability to manage trials of any size. We are also a CAP accredited/CLIA certified laboratory and we adhere to GCLP guidelines.
Our high-throughput laboratory can support your clinical trials with the capacity to process large sample volumes quickly, support studies with short set up timelines and provide rapid turnaround times. Our project managers and scientists act as part of your team – going above and beyond to get you the results you need when you need them. Accelerating your vaccine, compound, immune therapy or biological from bench to market.
Viracor Eurofins Biopharma Services is a trusted provider of drug development solutions to pharmaceutical and contract research organizations. We offer complex/esoteric testing and assay development, to help advance your Phase 1-4 clinical trials through trusted partnership, scientific excellence and exceptional service.
For more than 30 years, Viracor has been dedicated to helping clients by providing high quality, accurate results to evaluate the effects of drug candidates across all major therapeutic categories. We offer broad experience in molecular infectious disease testing, vaccine safety and efficacy assessment, immunogenicity, cell-based assays, allergy/ hypersensitivity, and biomarker analysis. Our validated test list includes more than 3000, with new custom assays developed on a continual basis, in response to client needs. assays
NEW YORK – While vaccines for SARS-CoV-2 have rolled out at home and abroad, there is still uncertainty about their long-term effectiveness against the virus, and questions linger about whether a booster shot will be necessary and how often individuals will need to get vaccinated to remain protected against the virus.